Insider

Medtronic plc

MDT Health Care · 3 analyses

Medtronic reported $9.8B in revenue (+13.7% YoY), compared with a +7.2% median across covered Health Care peers. 3 insider sales recorded.

Mentioned in recent filings: Ukraine Russia Tariffs

What changed

What changed

Medtronic announces final exchange ratio for MiniMed shares

Medtronic plc commenced an exchange offer on September 14, 2026, under which up to 225,361,295 newly issued MiniMed shares may be exchanged for Medtronic common shares. On October 7, 2026 the company announced the final ratio — 4.5939 MiniMed shares for each Medtronic share, which determines the size of the future issuance and the potential reduction of Medtronic shares.

· Medtronic plc

Company history

October 2026

Medtronic plc: 12 recorded developments from 2 official sources in 2026-10.

  • 2026-09-17: To obtain copies of the Prospectus and related documents, or for questions about the terms of the Exchange Offer or how to participate, you may contact the information agent at (877) 361-7972 (toll-free for shareholders) or (646) 845-0146 (banks, brokers and all others outside the United Source
  • 2026-09-17: Medtronic plc commenced an offer to exchange up to 225,361,295 newly issued shares of common stock, par value $0.01 per share (MiniMed Common Stock), of MiniMed Group, Inc. for outstanding ordinary shares of Medtronic, par value $0.0001 per share, upon the terms and subject to the condit Source
  • 2026-09-17: Medtronic is filing this Current Report on Form 8-K to correct the Prospectus as set forth below, with new text within restated disclosures highlighted with bold, underlined text and deleted text bold and stricken-through. Source
  • 2026-09-17: MiniMed filed a Registration Statement on Form S-4 that includes a Prospectus, and the Exchange Offer is made solely by the Prospectus. Source
  • 2026-09-17: Holders of Medtronic Ordinary Shares may obtain a copy of the Prospectus by clicking on the appropriate link on http://www.dfking.com/MDTSeparation. Source
  • 2026-09-17: Medtronic has retained D.F. King & Co., Inc. as the information agent for the Exchange Offer. Source
  • 2026-10-19: Michael Marinaro will assume oversight responsibility for the Company’s Greater China operations, which will continue to be managed locally by Alex Gu. Source
  • 2026-10-19: Michael Marinaro's annual base salary was increased to $1,000,000 for fiscal year 2027. Source
  • 2026-10-19: The Committee approved supplemental fiscal year 2027 long-term incentive awards for Michael Marinaro with an aggregate target value of approximately $3.25 million. Source
  • 2026-10-19: The performance share unit award granted to Michael Marinaro will vest on April 27, 2029, based on fiscal year 2027 through fiscal year 2029 performance. Source
  • 2026-10-19: Shareholders elected twelve directors at the Annual General Meeting held on October 15, 2026, to hold office until the 2027 Annual General Meeting. Source
  • 2026-10-19: The exchange offer relating to the separation of MiniMed Group, Inc. settled and the separation is complete as of October 15, 2026. Source

Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.

Key figures

From the 10-Q for the period ended July 31, 2026, filed September 3, 2026. SEC

LatestEarlierChange
Revenue quarter$9.8B$8.6B+13.7%
Operating income quarter$1.8B$1.4B+22.1%
Net income quarter$1.5B$1B+41.3%
Diluted EPS quarter$1.14$0.81+40.7%
Operating cash flow quarter$1.8B$1.1B+64.8%
Cash and cash equivalents balance$1.7B$1.9B-13.2%

Next results expected around December 3, 2026 (estimate: the quarter ending about October 30, 2026 plus the 34 days the last report took). The company announces the actual date.

As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV

Sector peers

How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.

CompanyLatest revenueRevenue YoYOperating margin
Medtronic plc MDT$9.8B+13.7%18.1%
Unitedhealth Group Inc UNH$113B-0.4%5.8%
Mckesson Corp MCK$111B+7.6%1.4%
CVS Health Corp CVS$108B+5.4%3.3%
Cigna Group CI$73.7B+5.6%3.3%
Cardinal Health Inc CAH$67.5B+5.5%1.1%
Elevance Health, Inc. ELV$51.4B+1.4%2.5%

Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.

Governance events

Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.

DateEventFiling
October 19, 2026Director or officer departure or appointment (8-K item 5.02)8-K

As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.

Insider trades

DatePersonTradeSharesAvg. priceValueFiling
October 15, 2026Geoffrey MarthaSale 10b5-1 plan notice filed50,000$95.00$4,750,000SEC
October 15, 2026Michael MarinaroSale 10b5-1 plan notice filed10,420$96.00$1,000,320SEC
September 16, 2026Harry Skip KiilSale notice filed1,483$93.65$138,883SEC

All insider trades →

Large funds (13F)

FundSharesValueChange in sharesQuarter
BlackRock118,770,885$10,248,739,689+4.2%Q3 2026
State Street65,987,354$5,741,305,775+4.1%Q3 2026
Geode Capital Management30,879,777$2,654,207,843+2.3%Q3 2026
Norges Bank (Norway's sovereign fund)16,551,016$1,294,785,982—Q2 2026
Capital Research Global Investors12,109,295$1,044,914,582-8.7%Q3 2026
Millennium Management7,772,366$670,677,462+746.2%Q3 2026
Wellington Management6,548,154$565,040,209+1.1%Q3 2026
Citadel Advisors3,773,088$325,579,764-29.8%Q3 2026
Fidelity (FMR)3,009,048$259,650,702-9.2%Q3 2026
Two Sigma Investments2,117,561$182,724,339-34.7%Q3 2026
Renaissance Technologies887,841$76,611,800-72.0%Q3 2026
D. E. Shaw & Co.795,277$68,624,452-81.9%Q3 2026
Bridgewater Associates488,043$42,113,230+1.1%Q3 2026
T. Rowe Price9,209,495$794,688+21.6%Q3 2026

From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.